Nadeem Moiz
このコンテンツはまだ日本語訳がありません。
Nadeem Moiz is Chief Executive Officer of Revance. In the Botulinum Index graph, he represents the current Revance leadership node after Crown Laboratories’ 2025 acquisition of Revance Therapeutics.
His role matters because Revance / Crown Laboratories now combines the Revance name, Crown ownership context, and Daxxify product history. Moiz is therefore more useful as a current-company structure anchor than as the historical executive associated with Daxxify’s original FDA approval.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Revance |
| Current role | Chief Executive Officer |
| Company context | Revance within the Crown Laboratories corporate group |
| Relevant company node | Revance / Crown Laboratories |
| Relevant brand node | Daxxify |
| Official leadership source | Revance: Leadership Team and Board of Directors 🔗 |
Career Notes
Section titled “Career Notes”- Revance identifies Moiz as Chief Executive Officer on its current leadership page.
- Revance’s company timeline states that Crown acquired Revance and its aesthetics and therapeutic offering in 2025.
- The post-acquisition company presents itself as a privately held, fully integrated global company with products across aesthetics, skincare, and therapeutics.
- Daxxify remains the botulinum toxin product that links current Revance leadership to the toxin industry graph.
Post-Acquisition Revance Context
Section titled “Post-Acquisition Revance Context”Moiz’s page helps separate current corporate identity from Revance Therapeutics’ public-company history. After Crown’s acquisition, Revance is best read as a current operating and portfolio context inside the Crown Laboratories group, while Revance Therapeutics remains important to Daxxify’s development, approval, and commercialization history.
That distinction is useful for readers asking whether Revance still exists, whether Daxxify changed ownership context, or whether Crown’s acquisition changed the product’s regulatory identity. The acquisition changed company structure, not Daxxify’s product-specific label.
Activity and Public Context
Section titled “Activity and Public Context”Current Revance materials place Moiz at the head of a broader leadership team that spans finance, technology, operations, innovation, revenue, marketing, and scientific leadership. For toxin-market interpretation, the main connection is Daxxify: a Revance-developed daxibotulinumtoxinA-lanm product now interpreted inside the post-acquisition Revance / Crown company context.
Moiz should not be used as a shortcut for clinical claims about Daxxify. Product indications, unit cautions, and safety language belong to the prescribing information and FDA record.